Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Hopes BioNTech Pact Can Help Reboot Cancer Prospects

This article was originally published in Scrip

Executive Summary

Working hard to re-boot its cancer strategy, Sanofi SA of France has entered its latest multi-year collaboration in the field, this time with German biotech BioNTech AG to discover and develop up to five immunotherapies, each consisting of a mixture of synthetic messenger RNAs (mRNAs).


Related Content

Sanofi Takes €80M BioNTech Stake & Extends 2015 Deal
Genentech, BioNTech Pact Aims To Make Targeted Cancer Vaccines


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts